Platinum resistant ovarian cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Due to platinum resistance, the prognosis for about half of these patients is unfortunate. Platinum resistance currently poses a significant obstacle to the treatment of ovarian cancer. The most lethal gynecological cancer is epithelial ovarian cancer (EOC). The majority of patients (60%) have advanced disease when they are finally diagnosed, and because there aren't any obvious symptoms, the five-year survival rate is only about 30%. Despite being one of the most chemo-responsive tumors, epithelial ovarian cancer responds well to both cisplatin and carboplatin, patients almost always relapse with platinum resistant tumors after an initial response.

Description

Historically, platinum resistant ovarian cancer was defined as a disease recurrence within six months of the end of first-line platinum-based chemotherapy. However, this term is now used more broadly to refer to patients who progress within six months of receiving multiple lines of chemotherapy. The high mortality-to-incidence ratio in ovarian cancer is a result of resistance to platinum-based chemotherapy, which is a significant clinical challenge. Due to various underlying molecular mechanisms, management of the platinum-resistant disease has proven challenging. The prognosis for about half of these patients is sadly poor due to platinum resistance. Platinum resistance in ovarian cancer therapy at the moment is a major issue. The most lethal gynecological cancer is epithelial ovarian cancer (EOC). Initially, it is successfully treated with the DNA-damaging first-line therapies carboplatin and cisplatin. Patients do, however, almost always experience a relapse with a tumor that is resistant to further treatment with platinum-containing medication. Even though the majority of patients benefit from front-line platinum therapy, up to 25% of women with ovarian cancer have innately (or primary) platinum-refractory disease. These patients will eventually experience recurrence and progressive resistance, which is unfortunate.

Platinum resistant ovarian cancer (Epidemiology)

Because there aren't any obvious symptoms, the majority of patients (60%) have advanced disease when they are finally recognized, and the five-year survival rate is only about 30%. Although the phrase "Platinum Resistant" ovarian cancer is now more widely used to describe patients who advance within 6 months of receiving multiple lines of chemotherapy, it was formerly used to describe a disease recurrence within 6 months of the end of first-line platinum-based chemotherapy. Poor prognoses are typical for patients with PROC, with median survival times of less than 12 months and low rates of response to additional chemotherapy.

Platinum resistant ovarian cancer-Current Market Size & Forecast Trends

The market for platinum-resistant ovarian cancer is projected to experience significant growth, with estimates suggesting a current value of approximately USD 2.50 billion in 2023. This market is expected to reach around USD 5.45 billion by 2033, reflecting a compound annual growth rate (CAGR) of 8.10% during this period. The increasing incidence of ovarian cancer, particularly among patients who develop resistance to platinum-based therapies, is driving market expansion. Advances in treatment options, including the adoption of PARP inhibitors and targeted therapies, are also contributing to this growth. The evolving understanding of platinum resistance, including the nuances in patient responses to therapy, is expected to influence treatment strategies and market dynamics significantly. Overall, the platinum-resistant ovarian cancer market is well-positioned for substantial growth through 2035, supported by ongoing research and the development of innovative therapies tailored for resistant cases.

Platinum agents have long been the standard of care for epithelial ovarian cancer (EOC), fallopian tube, and primary peritoneal cancers at any stage. The next course of treatment is determined by the disease's sensitivity to or resistance to platinum-based medications. Platinum-containing medications, such as cisplatin, carboplatin, and oxaliplatin, are extremely effective treatments for a variety of cancers (e.g., testicular germ line, ovarian, lung, head and neck, and colon). The platinum-taxanes doublet (in both adjuvant and neo-adjuvant settings) is the gold standard therapy for epithelial ovarian cancer (EOC). Even though epithelial ovarian cancer is one of the most chemo-responsive tumors, responding well to both cisplatin and carboplatin, patients almost always relapse with platinum resistant tumors after an initial response. The alteration of drug efflux (for example, by controlling the expression of the copper transporter CTR-1), the alteration of intracellular proteins able to bind and sequester Pt (such as GSH), and the altered expression of pro- or anti-survival proteins have all been linked to resistance to platinum-containing drugs.

Report Highlights

Platinum resistant ovarian cancer- Current Market Trends

Platinum resistant ovarian cancer- Current & Forecasted Cases across the G8 Countries

Platinum resistant ovarian cancer- Market Opportunities and Sales Potential for Agents

Platinum resistant ovarian cancer- Patient-based Market Forecast to 2035

Platinum resistant ovarian cancer- Untapped Business Opportunities

Platinum resistant ovarian cancer- Product Positioning Vis-a-vis Competitors' Products

Platinum resistant ovarian cancer- KOLs Insight